Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. The gene discussed is CSNK2A1; the disease is T-cell acute lymphoblastic leukemia.